Brief: Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study
19/05/2025 13:18
May 19 (Reuters) - Alzamend Neuro Inc ALZN.O: ALZAMEND NEURO ENROLLS FIRST PATIENT IN ITS PHASE II CLINICAL TRIAL OF AL001 “LITHIUM IN BRAIN” STUDY TAKING PLACE AT MASSACHUSETTS GENERAL HOSPITAL ALZAMEND NEURO INC - TOPLINE DATA FOR AL001 EXPECTED BY YEAR END Source text: ID:nGNX8bLmB2 Further company coverage: ALZN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview